Logo

Tristan Orpin, Randy Armant, Richard Shippy, Sascha Drewlo

Jul 18, 2019

NIPT startup Cradle Genomics of San Diego announced its management team this week.

Tristan Orpin is the firm's CEO. Previously, he was chief commercial officer and executive VP of clinical genomics at Illumina. Prior to that, he held executive positions at Sequenom and at Bio-Rad Laboratories. Orpin has a BSc in genetics and biochemistry from the University of Melbourne.

Randy Armant is a cofounder and the firm's VP of research. He is a professor of obstetrics and gynecology at Wayne State University. Armant holds a PhD in developmental biology and biochemistry from Virginia Tech.

Richard Shippy is a cofounder and the company's VP of commercial. Previously, he was the senior director of strategic product marketing in reproductive and genetic health at Illumina. Before that, he held management positions in clinical market development at Affymetrix and at GE Healthcare. Shippy holds an MSc in biochemistry from Northern Illinois University.

Sascha Drewlo is a cofounder and Cradle's VP of development. He holds a PhD in molecular and cell biology from the German Sport University Cologne and an MSc in microbiology and genetics from the University of Münster.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.